Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of early measles-mumps-rubella vaccination at 6 months of age
2026-526160-21-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of measles, mumps, and rubella vaccine (live) in measles, mumps and rubella, sponsored by Rigshospitalet. Planned start Jun 2026; status: authorised.
02
Drugs
measles, mumps, and rubella vaccine (live)
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on 2026-526160-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526160-21-00.